Figure 5.

Utilization of AML-specific genetic markers to interrogate cell populations throughout reprogramming toward generation of healthy blood cells for transplantation. (A): Experimental strategy developed here to generate and characterize AML patient-specific HPCs that are capable of normal in vitro differentiation to the myeloid lineage and are devoid of leukemia-associated aberration found in matched patient bone marrow. As represented by dashed arrow, technological advances in cellular reprogramming may provide novel autologous blood sources for transplantation that circumvent limitations associated with current transplantation options used during AML therapy (denoted in red font). FISH results associated with presence (+) versus absence (−) of leukemia-associated aberration are indicated above cell populations. Abbreviations: AML, acute myeloid leukemia; GVHD, graft-versus host disease; HSC, hematopoietic stem cell.